Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

818
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
818
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

625
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
625

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced Automated Model for Robust Bone Marrow Segmentation in Whole-body MRI.

Academic radiology·2025
Same author

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.

Leukemia·2025
Same author

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial.

Blood·2025
Same author

Radiomics and Artificial Intelligence Landscape for [<sup>18</sup>F]FDG PET/CT in Multiple Myeloma.

Seminars in nuclear medicine·2024
Same author

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

The New England journal of medicine·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Related Experiment Video

Updated: Nov 11, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K

[Multiple myeloma-soon curable?]

Hartmut Goldschmidt1

  • 1Medizinische Klinik V und Nationales Centrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. hartmut.goldschmidt@med.uni-heidelberg.de.

Der Internist
|March 30, 2021
PubMed
Summary
This summary is machine-generated.

Multiple myeloma treatments have evolved significantly, with new therapies like monoclonal antibodies and CAR T-cell treatments improving outcomes and potentially leading to cures. Advanced imaging and biomarkers aid in personalized treatment strategies for better patient prognosis.

Keywords:
Diagnostic imagingImmunotherapy, adoptiveMinimal residual diseaseMonoclonal antibodiesMultiple myeloma/treatment monitoring

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K

Related Experiment Videos

Last Updated: Nov 11, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma (MM) is a common hematologic malignancy with evolving treatment paradigms over six decades.
  • Therapies have advanced from alkylating agents to stem cell transplantation, immunomodulatory drugs, and proteasome inhibitors.

Purpose of the Study:

  • To review the recent advancements in multiple myeloma treatment.
  • To highlight the impact of novel therapies on patient prognosis and potential for cure.
  • To discuss the role of biomarkers and imaging in current and future treatment strategies.

Main Methods:

  • Review of recent clinical studies and therapeutic advancements in multiple myeloma.
  • Analysis of the impact of novel agents, including monoclonal antibodies and CAR T-cell therapy.
  • Evaluation of diagnostic and prognostic parameters such as serum free light chains, MRI, and chromosomal alterations.

Main Results:

  • Monoclonal antibodies have expanded treatment options, leading to more frequent long-term remissions.
  • Immuno-oncological advancements are improving the prognosis for patients with previously poor life expectancy.
  • Emerging therapies like CAR T-cell treatment and novel antibody constructs show promise for improved outcomes and potential cures.

Conclusions:

  • Multiple myeloma treatment is transitioning towards more effective immuno-oncological approaches.
  • Biomarkers and advanced imaging (MRI) are crucial for treatment decisions and prognosis.
  • The future outlook for multiple myeloma suggests a potential for curability with ongoing therapeutic innovations.